Lanreotide
Lanreotide is a synthetic somatostatin analog. Like natural somatostatin, it inhibits various endocrine, neuroendocrine, and exocrine mechanisms. It reduces the levels of growth hormone (GH) and insulin-like growth factor-1 (IGF-1), making it effective in managing acromegaly and slowing the growth of certain neuroendocrine tumors.
Dosage by Body Weight
Administered only by deep subcutaneous injection, typically in the superior external quadrant of the buttock, by a healthcare professional. For acromegaly, the recommended starting dose is 90 mg every 4 weeks, adjusted based on clinical response and hormone levels. For GEP-NETs, the recommended dose is 120 mg every 4 weeks.
- Body Weight
- Below 5 kg
- Dose
- Not recommended
- Frequency
- N/A
- Tracking Notes
- Safety and effectiveness of Lanreotide in pediatric patients have not been established.
- Body Weight
- 5-7 kg
- Dose
- Not recommended
- Frequency
- N/A
- Tracking Notes
- Safety and effectiveness of Lanreotide in pediatric patients have not been established.
- Body Weight
- 8-10 kg
- Dose
- Not recommended
- Frequency
- N/A
- Tracking Notes
- Safety and effectiveness of Lanreotide in pediatric patients have not been established.
- Body Weight
- 11-15 kg
- Dose
- Not recommended
- Frequency
- N/A
- Tracking Notes
- Safety and effectiveness of Lanreotide in pediatric patients have not been established.
- Body Weight
- 16-20 kg
- Dose
- Not recommended
- Frequency
- N/A
- Tracking Notes
- Safety and effectiveness of Lanreotide in pediatric patients have not been established.
| Body Weight | Dose | Frequency | Tracking Notes |
|---|---|---|---|
| Below 5 kg | Not recommended | N/A | Safety and effectiveness of Lanreotide in pediatric patients have not been established. |
| 5-7 kg | Not recommended | N/A | Safety and effectiveness of Lanreotide in pediatric patients have not been established. |
| 8-10 kg | Not recommended | N/A | Safety and effectiveness of Lanreotide in pediatric patients have not been established. |
| 11-15 kg | Not recommended | N/A | Safety and effectiveness of Lanreotide in pediatric patients have not been established. |
| 16-20 kg | Not recommended | N/A | Safety and effectiveness of Lanreotide in pediatric patients have not been established. |
Formulation
Purpose
Used for the long-term treatment of acromegaly in patients who have had an inadequate response to or cannot receive surgery or radiotherapy. Also indicated for the treatment of patients with unresectable, well- or moderately-differentiated, locally advanced or metastatic gastroenteropancreatic neuroendocrine tumors (GEP-NETs) to improve progression-free survival.
Generic Name
LanreotideBranded Drug Names
Lanreotide is listed as a generic drug name. Common branded medicines that may contain the same active ingredient include:
Scheduled Drug
No. This medicine is generally not treated as a scheduled/prescription-only drug in common consumer references, but local rules may vary.